Astrana Health, Inc. (ASTH)
Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists. The company serves patients primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was founded in 1992 and is headquartered in Alhambra, California.
- Symbol
- ASTH
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Market cap
- $1.72B
- 52 week range
- 18.08 - 51.6
Valuation
- Share price
- $33.72 (close of 2026-09-23)
- P/E (TTM)
- 42.30x
- Price to book
- 2.05x
- Price to free cash flow
- 18.27x
- Enterprise value
- $2.30B
- Book value per share
- $17.12
Price performance
| Period | Change |
|---|
| 1 day | +0.51% |
| 5 days | -12.07% |
| 1 month | -14.31% |
| 3 months | -18.16% |
| 6 months | +41.62% |
| Year to date | +35.91% |
| 1 year | +22.00% |
| 3 years | +12.63% |
| 5 years | -65.01% |
| 10 years | +712.53% |
| All time | +258.72% |
Profitability and growth
- Return on equity
- 2.83%
- Return on invested capital
- 4.37%
- Return on assets
- 1.01%
- Return on capital employed
- 4.90%
- Gross margin
- 9.30%
- Net margin
- 0.71%
- EBITDA margin
- 3.91%
- Revenue growth
- 56.39%
- Net income growth
- -47.89%
- Free cash flow growth
- 136.58%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 5.47%
- Current ratio
- 1.23x
- Net debt to EBITDA
- 3.04x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $3.18B
- Cost of revenue
- $2.89B
- Gross profit
- $295.78M
- EBITDA
- $124.27M
- Net income
- $22.49M
- Earnings per share
- $0.46
- Shares outstanding
- 49.08M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $3.18B | $295.78M | $22.49M | $0.46 |
| 2024-12-31 | $2.03B | $243.46M | $43.15M | $0.91 |
| 2023-12-31 | $1.39B | $197.21M | $60.72M | $1.30 |
| 2022-12-31 | $1.14B | $181.94M | $45.17M | $1.00 |
| 2021-12-31 | $773.91M | $177.77M | $68.92M | $1.57 |
| 2020-12-31 | $687.18M | $147.97M | $37.69M | $1.03 |
| 2019-12-31 | $560.62M | $92.81M | $14.12M | $0.41 |
| 2018-12-31 | $519.91M | $158.78M | $10.84M | $0.33 |
| 2017-12-31 | $356.36M | $82.90M | $25.80M | $1.01 |
| 2017-03-31 | $57.43M | $8.69M | $-8.97M | $-1.49 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 9.30% | 0.71% | 2.83% | 4.37% |
| 2024-12-31 | 11.97% | 2.12% | 6.02% | 6.50% |
| 2023-12-31 | 14.22% | 4.38% | 9.85% | 8.17% |
| 2022-12-31 | 15.90% | 3.95% | 8.30% | 13.05% |
| 2021-12-31 | 22.97% | 8.91% | 15.18% | 15.76% |
| 2020-12-31 | 21.53% | 5.48% | 11.44% | 10.15% |
| 2019-12-31 | 16.56% | 2.52% | 7.34% | 7.02% |
| 2018-12-31 | 30.54% | 2.08% | 5.97% | 78.98% |
| 2017-12-31 | 23.26% | 7.24% | 15.72% | 48.51% |
| 2017-03-31 | 15.14% | -15.62% | -3317.63% | -696.44% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $429.47M | $990.90M |
| 2024-12-31 | $288.45M | $425.30M |
| 2023-12-31 | $293.81M | $258.94M |
| 2022-12-31 | $288.03M | $203.39M |
| 2021-12-31 | $233.10M | $182.92M |
| 2020-12-31 | $193.47M | $230.21M |
| 2019-12-31 | $103.19M | $232.17M |
| 2018-12-31 | $106.89M | - |
| 2017-12-31 | $99.75M | - |
| 2017-03-31 | $8.66M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $104.49M | $38.60M |
| 2024-12-31 | $44.17M | $34.54M |
| 2023-12-31 | $39.70M | $22.04M |
| 2022-12-31 | $59.19M | $16.10M |
| 2021-12-31 | $51.11M | $6.75M |
| 2020-12-31 | $45.00M | $3.38M |
| 2019-12-31 | $12.63M | $1.55M |
| 2018-12-31 | $24.33M | $1.44M |
| 2017-12-31 | $49.75M | $2.74M |
| 2017-03-31 | $-8.44M | $1.11M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-05
- Consensus EPS estimate
- $0.44
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-06 | Jun/2026 | $0.31 |
| 2026-05-07 | - | - |
| 2026-03-02 | - | - |
| 2025-11-06 | - | - |
| 2025-08-07 | - | - |
| 2025-05-08 | - | - |
| 2025-02-27 | - | - |
| 2025-02-25 | - | - |
Filings and sources
- Company website
- astranahealth.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
HCA Healthcare, Inc. (HCA) · DaVita Inc. (DVA) · Universal Health Services Inc (UHS) · Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades